221 related articles for article (PubMed ID: 3004993)
1. Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent.
Weishaar RE; Quade M; Schenden JA; Boyd DK; Evans DB
Eur J Pharmacol; 1985 Dec; 119(3):205-15. PubMed ID: 3004993
[TBL] [Abstract][Full Text] [Related]
2. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T
Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
[TBL] [Abstract][Full Text] [Related]
4. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043.
Kariya T; Wille LJ; Dage RC
J Cardiovasc Pharmacol; 1982; 4(3):509-14. PubMed ID: 6177950
[TBL] [Abstract][Full Text] [Related]
5. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
[TBL] [Abstract][Full Text] [Related]
6. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".
Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G
J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287
[TBL] [Abstract][Full Text] [Related]
7. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone.
Earl CQ; Linden J; Weglicki WB
J Cardiovasc Pharmacol; 1986; 8(4):864-72. PubMed ID: 2427830
[TBL] [Abstract][Full Text] [Related]
8. UD-CG 115--a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle.
Honerjäger P; Heiss A; Schäfer-Korting M; Schönsteiner G; Reiter M
Naunyn Schmiedebergs Arch Pharmacol; 1984 Mar; 325(3):259-69. PubMed ID: 6328334
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of the effects of MCI-154, a novel cardiotonic agent, on cardiac tissues.
Narimatsu A; Kitada Y; Satoh N; Morita M; Muroyama A; Kobayashi M; Ohizumi Y
Jpn J Pharmacol; 1989 Mar; 49(3):397-405. PubMed ID: 2545964
[TBL] [Abstract][Full Text] [Related]
10. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
11. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart.
Hino M; Sugawara H; Yoshimura A; Ogura A; Yoshioka K; Sakato M; Endoh M
Arzneimittelforschung; 1999 May; 49(5):398-406. PubMed ID: 10367101
[TBL] [Abstract][Full Text] [Related]
12. Inotropic drugs and their mechanisms of action.
Scholz H
J Am Coll Cardiol; 1984 Aug; 4(2):389-97. PubMed ID: 6330195
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
Shahid M; Martorana MG; Cottney JE; Marshall RJ
Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
[TBL] [Abstract][Full Text] [Related]
14. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
15. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
Berger C; Meyer W; Scholz H; Starbatty J
Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
[TBL] [Abstract][Full Text] [Related]
16. Adenylyl cyclase-mediated effects contribute to increased Isoprenaline-induced cardiac contractility in TRPM4-deficient mice.
Uhl S; Mathar I; Vennekens R; Freichel M
J Mol Cell Cardiol; 2014 Sep; 74():307-17. PubMed ID: 24972051
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase-inhibiting properties of newer inotropic agents.
Scholz H; Meyer W
Circulation; 1986 Mar; 73(3 Pt 2):III99-108. PubMed ID: 2417748
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
[TBL] [Abstract][Full Text] [Related]
19. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
20. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
